舒洛地特加替米沙坦对2型糖尿病视网膜病变疗效观察

目的通过舒洛地特联合替米沙坦对2型糖尿病视网膜病变（diabeticretinopathy，DR）减少眼底微动脉瘤、延缓DR进展速度有效性的观察，评价舒洛地特和替米沙坦联合应用对DR的疗效。方法162例DR患者随机分为三组，替米沙坦组、舒洛地特组和联合治疗组，所有患者随访6个月，随访过程中定期检查眼底，空腹血糖、糖化血红蛋白、谷丙转氨酶、谷草转氨酶、纤维蛋白原。结果三组患者眼底微动脉瘤治疗后较治疗前均明显较少，差异有统计学意义（P〈0．05），治疗后三组间患者眼底微动脉瘤比较，差异无统计学意义（P〉0．05），联合治疗组与替米沙坦组、舒洛地特组相比，可延缓DR增殖型进展速度，差异有统计学意义（P〈0．05）。结论舒洛地特联合替米沙坦治疗DR能有效减少眼底微动脉瘤、延缓DR进展速度，疗效优于单一治疗组。

Effect observation of Sulodexide combined with Telmisartan in treatment of diabetic retinopathy

Objective To evaluate the curative effects of Sulodexide combined with Telmisartan in reducing miroaneu rysm and the progression of Type 2 diabetic retinopathy. Methods Totally 162 patients having been confirmed DR were divided into three treatment groups：Sulodexide group ,Telmisartan group and combination group, testing eye fundus ,fast ing plasma glucose, hemoglobin Alc, alanine aminotransferase, aspartate aminotransferase and fibringen at regular inter vals in the six months follow up Visit. Results Compared with those before the study, miroaneurysm significantly de scended in the total three groups （ P 〈 0. 05 ）. There is no statistical significance amang the three groups （ P 〉 0.05 ）. However, Sulodexide group and Telmisartan group reduced the rate of diabetic retinopathy progression significantly com pared with combination group, （ P 〈 0. 05 ）. Conclusion Sulodexide combined with Telmisartan can significantly de crease miroaneurysm and slow down the progression of diabetic retinopathy.